PURPOSE: To study the contrast agent dose sensitivity of hemodynamic parameters derived from brain dynamic susceptibility contrast MRI (DSC-MRI). MATERIALS AND METHODS: Sequential DSC-MRI (1.5T gradient-echo echo-planar imaging using an echo time of 61-64 msec) was performed using contrast agent doses of 0.1 and 0.2 mmol/kg delivered at a fixed rate of 5.0 mL/second in 12 normal subjects and 12 stroke patients. RESULTS: 1) Arterial signal showed the expected doubling in relaxation response (DeltaR2*) to dose doubling. 2) The brain signal showed a less than doubled DeltaR2* response to dose doubling. 3) The 0.2 mmol/kg dose studies subtly underestimated cerebral blood volume (CBV) and cerebral blood flow (CBF) relative to the 0.1 mmol/kg studies. 4) In the range of low CBV and CBF, the 0.2 mmol/kg studies overestimated the CBV and CBF compared with the 0.1 mmol/kg studies. 5) The 0.1 mmol/kg studies reported larger ischemic volumes in stroke. CONCLUSION: Subtle but statistically significant dose sensitivities were found. Therefore, it is advisable to carefully control the contrast agent dose when DSC-MRI is used in clinical trials. The study also suggests that a 0.1 mmol/kg dose is adequate for hemodynamic measurements.
PURPOSE: To study the contrast agent dose sensitivity of hemodynamic parameters derived from brain dynamic susceptibility contrast MRI (DSC-MRI). MATERIALS AND METHODS: Sequential DSC-MRI (1.5T gradient-echo echo-planar imaging using an echo time of 61-64 msec) was performed using contrast agent doses of 0.1 and 0.2 mmol/kg delivered at a fixed rate of 5.0 mL/second in 12 normal subjects and 12 strokepatients. RESULTS: 1) Arterial signal showed the expected doubling in relaxation response (DeltaR2*) to dose doubling. 2) The brain signal showed a less than doubled DeltaR2* response to dose doubling. 3) The 0.2 mmol/kg dose studies subtly underestimated cerebral blood volume (CBV) and cerebral blood flow (CBF) relative to the 0.1 mmol/kg studies. 4) In the range of low CBV and CBF, the 0.2 mmol/kg studies overestimated the CBV and CBF compared with the 0.1 mmol/kg studies. 5) The 0.1 mmol/kg studies reported larger ischemic volumes in stroke. CONCLUSION: Subtle but statistically significant dose sensitivities were found. Therefore, it is advisable to carefully control the contrast agent dose when DSC-MRI is used in clinical trials. The study also suggests that a 0.1 mmol/kg dose is adequate for hemodynamic measurements.
Authors: T Benner; P Reimer; G Erb; G Schuierer; S Heiland; C Fischer; V Geens; K Sartor; M Forsting Journal: J Magn Reson Imaging Date: 2000-09 Impact factor: 4.813
Authors: K Nael; A Meshksar; B Ellingson; M Pirastehfar; N Salamon; P Finn; D S Liebeskind; J P Villablanca Journal: AJNR Am J Neuroradiol Date: 2014-02-06 Impact factor: 3.825
Authors: K Nael; B Mossadeghi; T Boutelier; W Kubal; E A Krupinski; J Dagher; J P Villablanca Journal: AJNR Am J Neuroradiol Date: 2014-11-27 Impact factor: 3.825
Authors: Danny J J Wang; Jeffry R Alger; Joe X Qiao; Qing Hao; Samuel Hou; Rana Fiaz; Matthias Gunther; Whitney B Pope; Jeffrey L Saver; Noriko Salamon; David S Liebeskind Journal: Stroke Date: 2012-02-09 Impact factor: 7.914
Authors: Søren Christensen; Shalini Amukotuwa; Maarten G Lansberg; Stephanie Kemp; Jeremy J Heit; Michael Mlynash; Michael P Marks; Greg W Albers; Roland Bammer Journal: J Cereb Blood Flow Metab Date: 2020-03-24 Impact factor: 6.960
Authors: Gernot Reishofer; Karl Koschutnig; Christian Enzinger; Anja Ischebeck; Stephen Keeling; Rudolf Stollberger; Franz Ebner Journal: Magn Reson Med Date: 2010-10-06 Impact factor: 4.668